19:23 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella 1...
17:09 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Merck reports Phase Ia data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 7 evaluable patients with advanced solid tumors or metastases including lymphoma localized in the head and neck region or thorax in the Phase Ia portion of a Phase Ia/Ib...
02:31 , Jun 15, 2017 |  BC Week In Review  |  Clinical News

Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 25 evaluable patients with advanced solid tumors in a Phase I trial showing that oral M3814 (MSC 2490484A) led to 6 cases of stable disease lasting for ≥18 weeks....
16:15 , Jan 13, 2017 |  BC Week In Review  |  Company News

Vertex, Merck deal

Vertex granted Merck exclusive, worldwide rights to four cancer programs. Vertex will receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs' development and commercialization. The deal includes Vertex's...
00:17 , Jan 12, 2017 |  BC Extra  |  Company News

Vertex grants Merck KGaA rights to cancer programs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to four cancer programs. Vertex is to receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs'...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial showed that oral CC-115 led to 1 complete response in a...
07:00 , Jul 25, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ataxia telangiectasia mutated (ATM); DNA-dependent protein kinase (DNA-PK) Mouse and cell culture studies suggest inhibiting the...
07:00 , May 24, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase.1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline plc gives...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Company News

AstraZeneca, Cancer Research UK, University of Newcastle deal

AstraZeneca's KuDos Pharmaceuticals Ltd. subsidiary exercised a 2004 option for exclusive, worldwide rights to a portfolio of DNA-dependent protein kinase (DNA-PK) inhibitors jointly owned by the university and Cancer Research UK's Cancer...
07:00 , Aug 25, 2003 |  BioCentury  |  Product Development

KuDos: Demolition drug

Most chemotherapies are designed to kill tumor cells by causing fatal breaks in one or both DNA strands. However, like any other body cell, cancer cells can repair damaged DNA and thereby survive the attack....